| Objective:Discussion on the treatment of coronary Heart failure(HF)with metoprolol combined with trimetazidine.The effect of plasma b-type natriuretic peptide(BNP)on the clinical efficacy indicated that on the basis of standard treatment of Chronic heart failure(CHF),the addition of trimetazidine can effectively improve cardiac function and has a certain clinical value in improving clinical efficacy.Methods:Choose in December 2018 to June 2019 in our hospital heart hospitalized with heart function ?-level ? coronary heart disease in patients with CHF,the random number table method is adopted to research objects were divided into control group and the team every 40 people.The two groups were routinely treated with Angiotensin Converting Enzyme Inhibitors(ACEI),aldosterone receptor antagonists,diuretics,cardiac drugs,etc.On this basis,the control group was treated with metoprolol succinate orally,and the study group was treated with metoprolol combined with trimetazidine orally.The patients in the two groups were followed up for 6 months.Basic data of the two groups,plasma BNP,Left ventricular ejection fraction(LVEF)of echocardiography before and after treatment,and the test data of the 6-minute walking test were calculated.The relevant data before and after treatment were compared within the two groups,and the data after treatment were compared between the groups,and the overall efficacy was evaluated.Results:1.There was no significant difference between the study group and the control group in terms of age,gender,height,weight,blood pressure,blood lipid,blood glucose and smoking history(P>,0.05).2.Compared with before treatment,the LVEF value and the 6-minute walking distance of the two groups increased after treatment,and the BNP level decreased,which was statistically significant(P<0.05),indicating that the anti-chf treatment in both the control group and the study group had certain effects.3.After treatment,the LVEF value and 6-minute walking distance of the study group were higher than those of the control group,and the BNP level was lower than those of the control group,which was statistically significant(P<0.05),indicating that the clinical treatment effect of the study group was better than that of the control group.Conclusion:1.No matter in the control group or the study group,after antihf treatment,the plasma BNP,LVEF and 6-minute walking test data of the patients were statistically different from those before treatment,indicating that the cardiac function of patients receiving standard antichf treatment was improved.2.After treatment,the BNP,LVEF and 6-minute walking test data of the study group were statistically significant compared with the control group,indicating that trimetazidine has certain clinical value in the treatment of CHF of coronary heart disease and the improvement of efficacy. |
PDF Full Text Request